Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 1123-1140

  Roberti, María Paula ^a   Arriaga, Juan Martín ^a   Bianchini, Michele ^a   Quintá, Héctor Ramiro ^b   Bravo, Alicia Inés ^c   Levy, Estrella Mariel ^a   Mordoh, José ^a,b   Barrio, María Marcela ^a  

^a INSTITUTO ALEXANDER FLEMING   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^c Unidad de Inmunopatología   (Argentina)

Author keywords

Angiogenesis; Metastasis; Protein profile; Triple negative breast cancer

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; COLLAGENASE 3; CXCL1 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 3; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; VASCULOTROPIN A; VASCULOTROPIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSPLANTATION, HETEROLOGOUS; VIMENTIN;

EID: 84865847694     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21187     Document Type: Article

References (71)

1. Sørlie T. Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40:2667-75; PMID:15571950; http://dx.doi.org/10.1016/j.ejca.2004.08.021.
2. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68; PMID:20813035; http://dx.doi.org/10.1186/bcr2635.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34; PMID:17671126; http://dx.doi.org/10.1158/1078- 0432.CCR-06-3045.
4. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17:1082-9; PMID:21233401; http://dx.doi.org/10.1158/1078-0432.CCR-10-2560.
5. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellers TA, et al. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Clin Cancer Res 1999; 5:2698-703; PMID:10537332.
6. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006; 12:4185-91; PMID:16857790; http://dx.doi.org/10.1158/1078-0432. CCR-06-0353.
7. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009; 115:423-8; PMID:18543098; http://dx.doi.org/10.1007/s10549-008-0086-2.
8. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, Meric-Bernstam F, Buchholz TA, Hsu L, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol 2011; 29:2628-34; PMID:21606433; http://dx.doi.org/10.1200/JCO.2010.32.1877.
9. Aktas B, Müller V, Tewes M, Zeitz J, Kasimir-Bauer S, Loehberg CR, et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. Gynecol Oncol 2011; 122:356-60; PMID:21605893; http://dx.doi.org/10.1016/j.ygyno.2011. 04.039.
10. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res 2011; 17:2055-64; PMID:21307144; http://dx.doi.org/10.1158/1078-0432.CCR-10-1920.
11. Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13:838-44; PMID:18650259; http://dx.doi.org/10.1634/ theoncologist.2008-0048.
12. Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 2012; 30:593-9; PMID:22124109; http://dx.doi.org/10.1200/JCO.2010.33.8889.
13. Bover L, Barrio M, Slavutsky I, Bravo AI, Quintans C, Bagnati A, et al. Description of a new human breast cancer cell line, IIB-BR-G, established from a primary undifferentiated tumor. Breast Cancer Res Treat 1991; 19:47-56; PMID:1661624; http://dx.doi.org/10.1007/BF01975204.
14. Bover L, Barrio M, Bravo AI, Slavutsky I, Larripa I, Bolondi A, et al. The human breast cancer cell line IIB-BR-G has amplified c-myc and c-fos oncogenes in vitro and is spontaneously metastatic in vivo. Cell Mol Biol (Noisy-le-grand) 1998; 44:493-504; PMID:9620446.
15. Roberti MP, Barrio MM, Bravo AI, Rocca YS, Arriaga JM, Bianchini M, et al. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR. Breast Cancer Res Treat 2011; 130:465-75; PMID:21308409; http://dx.doi.org/10.1007/s10549-011- 1360-2.
16. Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, et al. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 2008; 15:762-72; PMID:18202702; http://dx.doi.org/10.1038/sj.cdd.4402305.
17. Mohammed RA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis. Br J Cancer 2007; 96:1092-100; PMID:17353919; http://dx.doi.org/10.1038/sj.bjc. 6603678.
18. Walton KL, Makanji Y, Chen J, Wilce MC, Chan KL, Robertson DM, et al. Two distinct regions of latency-associated peptide coordinate stability of the latent transforming growth factor-beta1 complex. J Biol Chem 2010; 285:17029-37; PMID:20308061; http://dx.doi.org/10.1074/jbc.M110.110288.
19. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14:163-76; PMID:10652271.
20. Hildenbrand R, Schaaf A. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 2009; 34:15-23; PMID:19082473.
21. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007; 6:1973-82; PMID:17620428; http://dx.doi.org/10.1158/1535-7163.MCT-07-0063.
22. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, et al. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res 2003; 63:290-5; PMID:12543776.
23. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissière F, Laune D, et al. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 2007; 9:R15; PMID:17261184; http://dx.doi.org/10.1186/bcr1648.
24. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25:387-408; PMID:17043764; http://dx.doi.org/10.1007/s10555-006-9004-4.
25. Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, et al. Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways. Proc Natl Acad Sci U S A 2011; 108:17655-60; PMID:21990345; http://dx.doi.org/10.1073/pnas.1101133108.
26. Taylor AP, Leon E, Goldenberg DM. Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement. Br J Cancer 2010; 103:82-9; PMID:20551949; http://dx.doi.org/10.1038/sj.bjc.6605746.
27. Chan AY, Raft S, Bailly M, Wyckoff JB, Segall JE, Condeelis JS. EGF stimulates an increase in actin nucleation and filament number at the leading edge of the lamellipod in mammary adenocarcinoma cells. J Cell Sci 1998; 111:199-211; PMID:9405304.
28. Zlotnik A, Burkhardt AM, Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011; 11:597-606; PMID:21866172; http://dx.doi.org/10.1038/nri3049.
29. Wilson J, Balkwill F. The role of cytokines in the epithelial cancer microenvironment. Semin Cancer Biol 2002; 12:113-20; PMID:12027583; http://dx.doi.org/10.1006/scbi.2001.0419.
30. Boon T, Van den Eynde B. Tumour immunology. Curr Opin Immunol 2003; 15:129-30; PMID:12633660; http://dx.doi.org/10.1016/S0952-7915(03)00010-4.
31. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007; 7:659-72; PMID:17721431; http://dx.doi.org/10.1038/ nrc2193.
32. O'Hayer KM, Brady DC, Counter CM. ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis 2009; 30:1841-7; PMID:19805574; http://dx.doi.org/10.1093/carcin/bgp198.
33. Koga T, Endo H, Miyamoto Y, Mukai M, Akira S, Inoue M. IGFBPs contribute to survival of pancreatic cancer cells under severely hypoxic conditions. Cancer Lett 2008; 268:82-8; PMID:18467023; http://dx.doi.org/10.1016/j.canlet.2008.03. 030.
34. Kashyap AS, Hollier BG, Manton KJ, Satyamoorthy K, Leavesley DI, Upton Z. Insulin-like growth factor-I:vitronectin complex-induced changes in gene expression effect breast cell survival and migration. Endocrinology 2011; 152:1388-401; PMID:21303956; http://dx.doi.org/10.1210/en.2010-0897.
35. McIntosh J, Dennison G, Holly JM, Jarrett C, Frankow A, Foulstone EJ, et al. IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J Biol Chem 2010; 285:38788-800; PMID:20851879; http://dx.doi.org/10.1074/jbc.M110.177311.
36. Baxter RC. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol Pathol 2001; 54:145-8; PMID:11376125; http://dx.doi.org/10.1136/mp.54.3.145.
37. Lee HY, Moon H, Chun KH, Chang YS, Hassan K, Ji L, et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. J Natl Cancer Inst 2004; 96:1536-48; PMID:15494604; http://dx.doi.org/10.1093/ jnci/djh286.
38. Kansra S, Ewton DZ, Wang J, Friedman E. IGFBP-3 mediates TGF beta 1 proliferative response in colon cancer cells. Int J Cancer 2000; 87:373-8; PMID:10897042; http://dx.doi.org/10.1002/1097-0215(20000801)87:3〈373::AID- IJC10〉3.0.CO;2-X.
39. McCaig C, Fowler CA, Laurence NJ, Lai T, Savage PB, Holly JM, et al. Differential interactions between IGFBP-3 and transforming growth factor-beta (TGF-beta) in normal vs cancerous breast epithelial cells. Br J Cancer 2002; 86:1963-9; PMID:12085194; http://dx.doi.org/10.1038/sj.bjc.6600355.
40. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996; 88:601-6; PMID:8609661; http://dx.doi.org/10.1093/jnci/88.9.601.
41. Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome. Breast Cancer Res 2005; 7:R119-29; PMID:15642160; http://dx.doi.org/10.1186/bcr963.
42. Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 2011; 17:5275-86; PMID:21712446; http://dx.doi.org/10.1158/1078-0432.CCR-10-2727.
43. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 2011; 208:519-33; PMID:21282379; http://dx.doi.org/10.1084/jem.20102049.
44. Donnini S, Machein MR, Plate KH, Weich HA. Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol 1999; 189:66-71; PMID:10451490; http://dx.doi.org/10.1002/(SICI)1096-9896(199909)189: 1〈66::AIDPATH390〉3.0.CO;2-X.
45. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9:239-52; PMID:19279573; http://dx.doi.org/10.1038/nrc2618.
46. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438:820-7; PMID:16341007; http://dx.doi.org/10.1038/nature04186.
47. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70:7042-52; PMID:20823155; http://dx.doi.org/10.1158/ 0008-5472.CAN-10-0522.
48. Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). [Review]. Oncol Rep 2005; 14:105-12; PMID:15944776.
49. Giannopoulou I, Mylona E, Kapranou A, Mavrommatis J, Markaki S, Zoumbouli Ch, et al. The prognostic value of the topographic distribution of uPAR expression in invasive breast carcinomas. Cancer Lett 2007; 246:262-7; PMID:17319000; http://dx.doi.org/10.1016/j.canlet.2006.03.003.
50. Lester RD, Jo M, Montel V, Takimoto S, Gonias SL. uPAR induces epithelial-mesenchymal transition in hypoxic breast cancer cells. J Cell Biol 2007; 178:425-36; PMID:17664334; http://dx.doi.org/10.1083/jcb.200701092.
51. Jo M, Takimoto S, Montel V, Gonias SL. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice. Am J Pathol 2009; 175:190-200; PMID:19497996; http://dx.doi.org/10.2353/ajpath. 2009.081053.
52. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65:7775-81; PMID:16140945.
53. Giulianelli S, Cerliani JP, Lamb CA, Fabris VT, Bottino MC, Gorostiaga MA, et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123:2518-31; PMID:18767044; http://dx.doi.org/10.1002/ ijc.23802.
54. Singer CF, Hudelist G, Gschwantler-Kaulich D, Fink-Retter A, Mueller R, Walter I, et al. Interleukin-1alpha protein secretion in breast cancer is associated with poor differentiation and estrogen receptor alpha negativity. Int J Gynecol Cancer 2006; 16(Suppl 2):556-9; PMID:17010072; http://dx.doi.org/10. 1111/j.1525-1438.2006.00695.x.
55. Lewis AM, Varghese S, Xu H, Alexander HR. Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med 2006; 4:48; PMID:17096856; http://dx.doi.org/10.1186/1479-5876-4-48.
56. Apte RN, Voronov E. Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 2002; 12:277-90; PMID:12147202; http://dx.doi.org/10.1016/S1044-579X(02)00014-7.
57. Nozaki S, Sledge GW Jr., Nakshatri H. Cancer cell-derived interleukin 1alpha contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000; 275:60-2; PMID:10944441; http://dx.doi.org/10.1006/bbrc.2000.3241.
58. Weilbaecher KN, Guise TA, McCauley LK. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11:411-25; PMID:21593787; http://dx.doi.org/10. 1038/nrc3055.
59. Kim KY, Baek A, Park YS, Park MY, Kim JH, Lim JS, et al. Adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production. Oncol Rep 2009; 22:1497-504; PMID:19885605.
60. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096-103; PMID:8837607; http://dx.doi.org/10.1038/nm1096-1096.
61. Gocheva V, Wang HW, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010; 24:241-55; PMID:20080943; http://dx.doi.org/10.1101/gad.1874010.
62. Bièche I, Chavey C, Andrieu C, Busson M, Vacher S, Le Corre L, et al. CXC chemokines located in the 4q21 region are up-regulated in breast cancer. Endocr Relat Cancer 2007; 14:1039-52; PMID:18045955; http://dx.doi.org/10.1677/ erc.1.01301.
63. Agarwal A, Tressel SL, Kaimal R, Balla M, Lam FH, Covic L, et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010; 70:5880-90; PMID:20570895; http://dx.doi.org/10.1158/0008-5472.CAN-09- 4341.
64. Thomson S, Petti F, Sujka-Kwok I, Mercado P, Bean J, Monaghan M, et al. A systems view of epithelial-mesenchymal transition signaling states. Clin Exp Metastasis 2011; 28:137-55; PMID:21194007; http://dx.doi.org/10.1007/s10585-010- 9367-3.
65. Cleveland DW, Monteiro MJ, Wong PC, Gill SR, Gearhart JD, Hoffman PN. Involvement of neurofilaments in the radial growth of axons. J Cell Sci Suppl 1991; 15:85-95; PMID:1824110.
66. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5:5-23; PMID:21147047; http://dx.doi.org/10.1016/j. molonc.2010.11.003.
67. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 2011; 24:157-67; PMID:21076464; http://dx.doi.org/10.1038/modpathol.2010.200.
68. Freimoser FM, Jakob CA, Aebi M, Tuor U. The MTT [3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide] assay is a fast and reliable method for colorimetric determination of fungal cell densities. Appl Environ Microbiol 1999; 65:3727-9; PMID:10427074.
69. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54; PMID:942051; http://dx.doi.org/10.1016/0003- 2697(76)90527-3.
70. Quintá HR, Maschi D, Gomez-Sanchez C, Piwien-Pilipuk G, Galigniana MD. Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth. J Neurochem 2010; 115:716-34; PMID:20796173; http://dx.doi.org/10.1111/j.1471-4159.2010.06970.x.
71. Simian M, Molinolo A, Lanari C. Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol 2006; 168:270-9; PMID:16400029; http://dx.doi.org/10.2353/ajpath.2006.050012.